Nexalin Technology (NXL) Cash from Financing Activities (2021 - 2026)
Nexalin Technology's (NXL) quarterly Cash from Financing Activities came in at $756421.0 in Q1 2026, up 44.48% quarter-over-quarter from $523550.0 in Q4 2025.
Nexalin Technology (NXL) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Nexalin Technology's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $756421.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $756421.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.2 million, up 14.48% from the prior year.
- Cash from Financing Activities rose to $756421.0 in Q1 2026 per NXL's latest filing, from $523550.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $8.5 million in Q3 2022 and bottomed at -$200000.0 in Q1 2023.
- The 4-year median for Cash from Financing Activities is $261825.0 (2022), against an average of $1.6 million.
- Biggest YoY gain for Cash from Financing Activities was 200100.0% in 2023; the steepest drop was 200100.0% in 2023.
- Year by year, Cash from Financing Activities stood at $8.5 million in 2022, then tumbled by 102.35% to -$200000.0 in 2023, then surged by 361.78% to $523550.0 in 2025, then soared by 44.48% to $756421.0 in 2026.
- Per Business Quant, the three latest NXL Cash from Financing Activities figures stand at $756421.0 (Q1 2026), $523550.0 (Q4 2025), and -$200000.0 (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.39 Bn | 174.10 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 128.38 Bn | 125.50 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 107.68 Bn | 98.46 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 67.98 Bn | 66.53 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 47.81 Bn | 44.13 Bn | 1.29 Bn | -451.20 Mn |
| 6 | GE HealthCare Technologies | 28.53 Bn | 26.25 Bn | 1.98 Bn | 21.00 Mn |
| 7 | Dexcom | 28.35 Bn | 27.24 Bn | 750.30 Mn | -25.00 Mn |
| 8 | Smith & Nephew | 26.78 Bn | 26.20 Bn | - | - |
| 9 | Koninklijke Philips | 25.34 Bn | 22.21 Bn | 2.07 Bn | -26.93 Mn |
| 10 | Nexalin Technology | 9.52 Mn | 6.81 Mn | 13,133.00 | 756,421.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 756,421.00 |
| Mar 31, 2026 | 756,421.00 |
| Dec 31, 2025 | 523,550.00 |
| Dec 31, 2025 | 523,550.00 |
| Mar 31, 2023 | -200,000.00 |
| Mar 31, 2023 | -200,000.00 |
| Sep 30, 2022 | 8.52 Mn |
| Sep 30, 2022 | 8.52 Mn |
| Jun 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 100.00 |
| Mar 31, 2022 | 100.00 |
| Dec 31, 2021 | 934,443.00 |
| Dec 31, 2021 | 934,443.00 |